ALK B ALK-abello A/S Class B

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indberetter hermed følgende transaktioner:

1.Nærmere oplysninger om personen med ledelsesansvar/

personen med nær tilknytning til denne
a)NavnCarsten Hellmann
2.Årsag til indberetningen
a)Stilling/titelAdministrerende direktør
b)Første indberetning/ ændringFørste indberetning
3.Nærmere oplysninger om udstederen, deltageren på

markedet for emissionskvoter, auktionsplatformen,

auktionsholderen eller den auktionstilsynsførende
a)NavnALK-Abelló A/S
b)LEI529900SGCREUZCZ7P020
4.Nærmere oplysninger om transaktionen/transaktionerne:

gentages for i) hver type instrument, ii) hver type transaktion,

iii) hver dato og iv) hvert sted, hvor der er udført transaktioner
a)Beskrivelse af det finansielle instrument, instrumenttypen



Identifikationskode
Aktieoptioner



DK0060027142
b)Transaktionens artErhvervelse (udnyttelse af aktieoptioner)
c)Pris(er) og mængde(r)Pris(er)Mængde(r)
  15.770.832 DKK           17.068
d)Aggregerede oplysninger



- Aggregeret mængde



- Pris
 



        17.068 stk.



15.770.832 DKK
e)Dato for transaktionen2021-02-19
f)Sted for transaktionenNasdaq Copenhagen



                                                                                    ALK-Abelló A/S



For yderligere oplysninger kontakt venligst
:

Investor Relations: Per Plotnikof, mobil 2261 2525

 

Vedhæftet fil



EN
19/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-abello A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen

ALK-Abello (Buy, TP: DKK190.00) - Expecting solid start to the year

We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,606 shares at 155.680DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Jesper Ingildsen
  • Jesper Ingildsen

ALK-Abello (Buy, TP: DKK190.00) - Sales trump one-offs in Q4

While one-off costs took the initial focus (albeit broadly pre-warned), a solid underlying performance in Q4 was anchored in the important European tablet sales, which exceeded expectations. We find the 2025 guidance in line with expectations, but see upside risk to consensus on the top line given strong momentum in tablet sales in Europe. We reiterate our BUY and DKK190 target price.

Jesper Ingildsen
  • Jesper Ingildsen

ALK-Abello (Buy, TP: DKK190.00) - Expecting strong year end

We expect a strong Q4, with c12% organic revenue growth YOY, but the EBIT margin to be under pressure from well flagged one-offs related to optimisation initiatives and revision of its Chinese plans. We expect the 2025 guidance to be in line with expectations and its long-term strategy announced last year for >10% organic revenue growth and a c25% EBIT margin. We reiterate our BUY and DKK190 target price.

Jesper Ingildsen
  • Jesper Ingildsen

ALK-Abello (Buy, TP: DKK190.00) - Solid momentum reaffirmed

We find ALK’s solid momentum reaffirmed with the strong Q3 results, where higher European tablet sales more than offset the softness in SCIT/SLIT-drops. We believe the results also confirmed continued profitability improvement, leaving ALK on track to meet its 2025 EBIT margin target of c25% and in a position of strength to invest in growth opportunities, with the Neffy deal as a good example. We reiterate our BUY and DKK190 target price.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch